ALHC

TD Cowen analyst Ryan Langston maintains Alignment Healthcare (NASDAQ:ALHC) with a Buy and lowers the price target from $12 to $10.

Alignment Healthcare stock has been hit hard over the past few years, and with earnings now under a brighter spotlight, investors are asking whether the current valuation still lines up with the story they thought they owned. A steep share price reset plus questions around the quality of its reported profits turn the focus squarely onto what you are paying for the business's actual earnings power.

Health insurance company Alignment Healthcare (NASDAQ:ALHC) beat Wall Street’s revenue expectations in Q3 2026, with sales up 36.7% year on year to $1.36 billion. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $1.32 billion was less impressive, coming in 1.3% below expectations. Its non-GAAP profit of $0.05 per share was in line with analysts’ conse

Alignment Healthcare (ALHC) just released its third quarter 2026 report, pairing revenue of about US$1.36b with a net loss of US$8.05m, along with updated guidance that lifts full year sales expectations. The short-term picture has been rough for Alignment Healthcare, with the share price down about 9.8% over the past week and roughly 64.1% lower year to date at US$7.27, as investors weigh strong

Alignment Healthcare (NasdaqGS:ALHC) saw its California HMO plan Star Rating downgraded by the Centers for Medicare & Medicaid Services, removing eligibility for quality bonus payments. The loss of quality bonus payments applies to the California HMO contract and affects revenue tied to CMS Star Rating linked incentives. A shareholder rights law firm has opened an investigation into whether Alignm

JP Morgan analyst John Stansel maintains Alignment Healthcare (NASDAQ:ALHC) with a Overweight and lowers the price target from $10 to $8.

Revenue surged 36.7% but profitability guidance fell as medical costs climbed.

Moby summary of Alignment Healthcare, Inc.'s Q3 2026 earnings call